Unicancer
Nicole Bouwyn has extensive experience in human resources, currently serving as DRH Groupe at UNICANCER since December 2018. Prior to this role, Nicole held the position of DRH at Institut de Cancérologie de l'Ouest from March 2006 to November 2018 and worked as Responsable ressources humaines at ASEA 49 from February 2001 to February 2006. Additionally, Nicole served as Controleur de gestion sociale at Conforama for a brief period in 2000 and was Responsable ressources humaines at Groupe Hexagone Sante from March 1991 to April 1999. Nicole started the career as Conseiller en reclassement at Usinor-Sacilor in 1990. Educational qualifications include a Master 2 in Ressources Humaines from IGR-IAE Rennes, a Master in Gestion des Entreprises from ESG Ecoles de commerce, and a Master 1 in Droit from Université de Rennes I.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries